|
1
|
Chereda B and Melo JV: Natural course and
biology of CML. Ann Hematol. 94 (Suppl 2):S107–S121.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hochhaus A, Larson RA, Guilhot F, Radich
JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F,
Fujihara S, et al: Long-term outcomes of imatinib treatment for
chronic myeloid leukemia. N Engl J Med. 376:917–927.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Waller CF: Imatinib mesylate. Recent
Results Cancer Res. 212:1–27. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chandran RK, Geetha N, Sakthivel KM,
Aswathy CG, Gopinath P, Raj TVA, Priya G, Nair JKKM and Sreedharan
H: Genomic amplification of BCR-ABL1 fusion gene and its impact on
the disease progression mechanism in patients with chronic
myelogenous leukemia. Gene. 686:85–91. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yurttas NO and Eskazan AE: Novel
therapeutic approaches in chronic myeloid leukemia. Leuk Res.
91(106337)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yan Z, Lai Z and Lin J: Anticancer
properties of traditional Chinese medicine. Comb Chem High
Throughput Screen. 20:423–429. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Moreira D, Teixeira SS, Monteiro MHD,
De-Oliveira AC and Paumgartten FJR: Traditional use and safety of
herbal medicines1. Rev Bras Farmacogn. 24:248–257. 2014.
|
|
8
|
van Agtmael MA, Eggelte TA and van Boxtel
CJ: Artemisinin drugs in the treatment of malaria: From medicinal
herb to registered medication. Trends Pharmacol Sci. 20:199–205.
1999.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Abiri R, Silva ALM, de Mesquita LSS, de
Mesquita JWC, Atabaki N, de Almeida EB Jr, Shaharuddin NA and Malik
S: Towards a better understanding of Artemisia vulgaris:
Botany, phytochemistry, pharmacological and biotechnological
potential. Food Res Int. 109:403–415. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ly BTK, Ly DM, Linh PH, Son HK, Ha NL and
Chi HT: Screening of medicinal herbs for cytotoxic activity to
leukemia cells. J BUON. 25:1989–1996. 2020.PubMed/NCBI
|
|
11
|
Li S, Ilaria RL Jr, Million RP, Daley GQ
and Van Etten RA: The P190, P210, and P230 forms of the BCR/ABL
oncogene induce a similar chronic myeloid leukemia-like syndrome in
mice but have different lymphoid leukemogenic activity. J Exp Med.
189:1399–1412. 1999.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ly BTK and Chi HT: The potential effects
of green tea (-)-epigallocatechin-3-gallate on overcoming
imatinib-resistance in chronic myeloid leukemia bearing BCR-ABL. Ho
Chi Minh City University of Education: J Sci. 14:134–142. 2017.
|
|
13
|
Ly BT, Chi HT, Yamagishi M, Kano Y, Hara
Y, Nakano K, Sato Y and Watanabe T: Inhibition of FLT3 expression
by green tea catechins in FLT3 mutated-AML cells. PLoS One.
8(e66378)2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mahavorasirikul W, Viyanant V,
Chaijaroenkul W, Itharat A and Na-Bangchang K: Cytotoxic activity
of Thai medicinal plants against human cholangiocarcinoma,
laryngeal and hepatocarcinoma cells in vitro. BMC Complement Altern
Med. 10(55)2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Arana-Trejo RM, Sánchez ER, Ignacio-Ibarra
G, de la Fuente EB, Garces O, Morales EG, Granados MC, Martínez RO,
Rubio-Borja ME, Anaya LS, et al: BCR/ABL p210, p190 and p230 fusion
genes in 250 Mexican patients with chronic myeloid leukaemia (CML).
Clin Lab Haematol. 24:145–150. 2002.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hehlmann R, Lauseker M, Saußele S,
Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C,
Gratwohl A, et al: Assessment of imatinib as first-line treatment
of chronic myeloid leukemia: 10-year survival results of the
randomized CML study IV and impact of non-CML determinants.
Leukemia. 31:1476–5551. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Branford S, Melo JV and Hughes TP:
Selecting optimal second-line tyrosine kinase inhibitor therapy for
chronic myeloid leukemia patients after imatinib failure: Does the
BCR-ABL mutation status really matter? Blood. 114:5426–5435.
2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Apperley JF: Part I: Mechanisms of
resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol.
8:1018–1029. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bray F, Laversanne M, Weiderpass E and
Soerjomataram I: The ever-increasing importance of cancer as a
leading cause of premature death worldwide. Cancer. 127:3029–3030.
2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mauro MJ and Druker BJ: STI571: Targeting
BCR-ABL as therapy for CML. Oncologist. 6:233–238. 2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Herbst RS: Erlotinib (Tarceva): An update
on the clinical trial program. Semin Oncol. 30:34–46.
2003.PubMed/NCBI
|
|
22
|
Cragg GM and Pezzuto JM: Natural products
as a vital source for the discovery of cancer chemotherapeutic and
chemopreventive agents. Med Princ Pract. 25 (Suppl 2):S41–S59.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Abad MJ, Bedoya LM, Apaza L and Bermejo P:
The artemisia L. Genus: A review of bioactive essential oils.
Molecules. 17:2542–2566. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sharmila K and Padma PR: Anticancer
activity of Artemisia vulgaris on hepatocellular carcinoma
(HepG2) cells. Int J Pharmacy Pharm Sci. 5:479–483. 2013.
|
|
25
|
Saleh AM, Aljada A, Rizvi SA, Nasr A,
Alaskar AS and Williams JD: In vitro cytotoxicity of Artemisia
vulgaris L. essential oil is mediated by a
mitochondria-dependent apoptosis in HL-60 leukemic cell line. BMC
Complement Altern Med. 14(226)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Erel SB, Şenol SK, Köse FA and Ballar P:
In vitro cytotoxic properties of six Artemisia L. species. Turk J
Pharm Sci. 8:247–252. 2011.
|
|
27
|
Deguchi Y, Kimura S, Ashihara E, Niwa T,
Hodohara K, Fujiyama Y and Maekawa T: Comparison of imatinib,
dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Leuk Res. 32:980–983. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Liu C, Nie D, Li J, Du X, Lu Y, Li Y, Zhou
J, Jin Y and Pan J: Antitumor effects of blocking protein
neddylation in T315I-BCR-ABL leukemia cells and leukemia stem
cells. Cancer Res. 78:1522–1536. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Burslem GM, Schultz AR, Bondeson DP, Eide
CA, Stevens SL, Druker BJ and Crews CM: Targeting BCR-ABL1 in
chronic myeloid leukemia by PROTAC-mediated targeted protein
degradationdual inhibition and degradation of BCR-ABL1. Cancer Res.
79:4744–4753. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Huang H, Weng H, Dong B, Zhao P, Zhou H
and Qu L: Oridonin triggers chaperon-mediated proteasomal
degradation of BCR-ABL in leukemia. Sci Rep. 7:1–12.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shibata N, Ohoka N, Tsuji G, Demizu Y,
Miyawaza K, Ui-Tei K, Akiyama T and Naito M: Deubiquitylase USP25
prevents degradation of BCR-ABL protein and ensures proliferation
of Ph-positive leukemia cells. Oncogene. 39:3867–3878.
2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Jiang S, Wang X, He Y, Huang H, Cao B,
Zhang Z, Liu J, Wang Q, Huang Z and Mao X: Suppression of USP7
induces BCR-ABL degradation and chronic myelogenous leukemia cell
apoptosis. Cell Death Dis. 12(456)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Carrà G, Panuzzo C, Crivellaro S, Morena
D, Taulli R, Guerrasio A, Saglio G and Morotti A: The targetable
role of herpes virus-associated ubiquitin-specific protease (HAUSP)
in p190 BCR-ABL leukemia. Oncol Lett. 12:3123–3126. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Efferth T, Dunstan H, Sauerbrey A, Miyachi
H and Chitambar CR: The anti-malarial artesunate is also active
against cancer. Int J Oncol. 18:767–773. 2001.PubMed/NCBI View Article : Google Scholar
|
